Richard Daverman

Richard Daverman

Editor

Latest from Richard Daverman

Eyes on Asia: Merck and BioNTech land Chinese bispecifics Eyes on Asia: Merck and BioNTech land Chinese bispecifics

byRichard Daverman

Dec 4, 2024

4 Min Read

Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast

byRichard Daverman

Nov 18, 2024

5 Min Read

All from Richard Daverman

Money

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript

byRichard Daverman, Editor

Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange

Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange

byRichard Daverman, Editor

Asian currency

Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator

Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator

byRichard Daverman, Editor

From east to west: Lilly plans incubators in China and UK

From east to west: Lilly plans incubators in China and UK

byMillie Nelson, Richard Daverman

Eyes on Asia: News from Sanofi, Bayer, AZ plus the return of VC?

News from Sanofi, Bayer, AZ plus the return of VC?

byRichard Daverman, Editor

Eyes on Asia: Shinyaku’s $735m DMD deal, Kite turns back in China, and more

Shinyaku’s $735m DMD deal, Kite turns back in China, and more

byRichard Daverman, Editor

Chinese flag — Photo

China biopharma faces a pause; how bad is it?

China biopharma mid-2023 market summary

byRichard Daverman, Editor

Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more

byRichard Daverman, Editor

Top five Asia biopharma deals: August 2024

Asia biopharma deals: August 2024

byRichard Daverman, Editor

Eyes on Asia: EpimAb sells T-cell, funding for TargetRx, Hygieai on the siRNA march

Eyes on Asia: News from EpimAb, TargetRx, Hygieai

byRichard Daverman, Editor

Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz

Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz

byRichard Daverman, Editor

Eyes on Asia: Mulititude out licenses, Huadong bulks up Abs, Merck and Kelun

Eyes on Asia: Multitude out licenses, Huadong bulks up Abs, Merck and Kelun

byRichard Daverman, Editor

Subscribe to Our Newsletters

Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.